Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

Attenuated poxviruses are safe and capable of expressing foreign antigens. Poxviruses are applied in veterinary vaccination and explored as candidate vaccines for humans. However, poxviruses express multiple genes encoding proteins that interfere with components of the innate and adaptive immune response. This manuscript describes two strategies aimed to improve the immunogenicity of the highly attenuated, host-range restricted poxvirus NYVAC: deletion of the viral gene encoding type-I interferon-binding protein and development of attenuated replication-competent NYVAC. We evaluated these newly generated NYVAC mutants, encoding HIV-1 env, gag, pol and nef, for their ability to stimulate HIV-specific CD8 T-cell responses in vitro from blood mononuclear cells of HIV-infected subjects. The new vectors were evaluated and compared to the parental NYVAC vector in dendritic cells (DCs), RNA expression arrays, HIV gag expression and cross-presentation assays in vitro. Deletion of type-I interferon-binding protein enhanced expression of interferon and interferon-induced genes in DCs, and increased maturation of infected DCs. Restoration of replication competence induced activation of pathways involving antigen processing and presentation. Also, replication-competent NYVAC showed increased Gag expression in infected cells, permitting enhanced cross-presentation to HIV-specific CD8 T cells and proliferation of HIV-specific memory CD8 T-cells in vitro. The recombinant NYVAC combining both modifications induced interferon-induced genes and genes involved in antigen processing and presentation, as well as increased Gag expression. This combined replication-competent NYVAC is a promising candidate for the next generation of HIV vaccines.

[1]  C. Sorzano,et al.  Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens , 2010, PloS one.

[2]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[3]  M. Esteban.  Attenuated poxvirus vectors MVA and NYVAC as promising vaccine cadidates against HIV/AIDS , 2009, Human vaccines.

[4]  M. Esteban,et al.  The interferon system and vaccinia virus evasion mechanisms. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  S. C. Rosa,et al.  ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. , 2009, Journal of immunological methods.

[6]  R. Steinman,et al.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant , 2009, The Journal of experimental medicine.

[7]  D. Filippov,et al.  Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity , 2009, Proceedings of the National Academy of Sciences.

[8]  G. Pantaleo,et al.  Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens , 2009, Journal of Virology.

[9]  A. Rothman,et al.  Corrigendum to “Vaccinia virus-specific CD8+ T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans” [Hum. Immunol. 69 (2007) 815–825] , 2009 .

[10]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[11]  A. Rothman,et al.  Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. , 2008, Human immunology.

[12]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[13]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[14]  S. McCormack,et al.  EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. , 2008, Vaccine.

[15]  Q. Sattentau,et al.  EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. , 2008, Vaccine.

[16]  M. Krupa,et al.  The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. , 2008, Current gene therapy.

[17]  S. McCormack,et al.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses , 2008, The Journal of experimental medicine.

[18]  R. Sékaly.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? , 2008, The Journal of experimental medicine.

[19]  J. Heeney,et al.  Differential CD4 (cid:1) versus CD8 (cid:1) T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates (cid:1) † , 2022 .

[20]  M. John,et al.  Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype , 2007, Proceedings of the National Academy of Sciences.

[21]  T. Schumacher,et al.  In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity , 2007, The Journal of Immunology.

[22]  T. Gallart,et al.  Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC , 2007, Journal of Virology.

[23]  G. Pantaleo,et al.  Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. , 2007, Vaccine.

[24]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[25]  G. Pantaleo,et al.  Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.

[26]  M. Esteban,et al.  Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene , 2006, Journal of Virology.

[27]  Jiang Fan,et al.  Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239 , 2006, Journal of Virology.

[28]  David Heckerman,et al.  Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes , 2006, Nature Immunology.

[29]  D. Koelle,et al.  Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans 1 2 , 2005, The Journal of Immunology.

[30]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Todd M. Allen,et al.  HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load , 2005, Journal of Virology.

[32]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[33]  M. Kuroda,et al.  Role of Genes That Modulate Host Immune Responses in the Immunogenicity and Pathogenicity of Vaccinia Virus , 2005, Journal of Virology.

[34]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[35]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[36]  Stephen J O'Brien,et al.  The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.

[37]  Todd M. Allen,et al.  Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses , 2003, Journal of Virology.

[38]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[39]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Tartaglia,et al.  Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. , 2002, Virology.

[41]  D. Montefiori,et al.  Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+ and CD8+ T Cell Responses1 , 2002, The Journal of Immunology.

[42]  D. Montefiori,et al.  Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy1 , 2002, The Journal of Immunology.

[43]  R. Siliciano,et al.  Direct Priming and Cross-Priming Contribute Differentially to the Induction of CD8+ CTL Following Exposure to Vaccinia Virus Via Different Routes1 , 2002, The Journal of Immunology.

[44]  A. Alcamí,et al.  The Vaccinia Virus Soluble Alpha/Beta Interferon (IFN) Receptor Binds to the Cell Surface and Protects Cells from the Antiviral Effects of IFN , 2000, Journal of Virology.

[45]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Schmitz,et al.  Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. , 1999, Journal of immunology.

[47]  R. Andino,et al.  Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen , 1999, Nature.

[48]  S. Hoffman,et al.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.

[49]  E. Paoletti.  Applications of pox virus vectors to vaccination: an update. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. McNeil,et al.  Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. , 1996, QJM : monthly journal of the Association of Physicians.

[51]  A. Alcamí,et al.  Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity , 1995, Journal of virology.

[52]  R. Buller,et al.  Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*) , 1995, The Journal of Biological Chemistry.

[53]  E. Paoletti,et al.  Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases , 1995, Journal of leukocyte biology.

[54]  A. Alcamí,et al.  Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity , 1995, Cell.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  B. Moss,et al.  Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant , 1994, Journal of virology.

[57]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[58]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[59]  E. Paoletti,et al.  Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. , 1994, Developments in biological standardization.

[60]  D. Spehner,et al.  Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. , 1993, The Journal of general virology.

[61]  M. Perkus,et al.  NYVAC: a highly attenuated strain of vaccinia virus. , 1992, Virology.

[62]  S. Goebel,et al.  Vaccinia virus host range genes. , 1990, Virology.

[63]  J. Eberwine,et al.  Amplified RNA synthesized from limited quantities of heterogeneous cDNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Persson,et al.  Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique. , 1978, Tissue antigens.